Pacific Center for Financial Services’s CRISPR Therapeutics CRSP Stock Holding History

Pacific Center for Financial Services’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-81	Closed	-$3.81K	–	489
2024 Q3	$3.81K	Hold	81	–	–	﹤0.01%	382
2024 Q2	$4.38K	Hold	81	–	–	﹤0.01%	364
2024 Q1	$5.52K	Hold	81	–	–	﹤0.01%	359
2023 Q4	$5.07K	Hold	81	–	–	﹤0.01%	312
2023 Q3	$3.68K	Hold	81	–	–	﹤0.01%	338
2023 Q2	$4.55K	Hold	81	–	–	﹤0.01%	322
2023 Q1	$3.66K	Buy	+81	New	+$3.93K	﹤0.01%	331
2022 Q3	$5K	Hold	81	–	–	﹤0.01%	324
2022 Q2	$5K	Hold	81	–	–	﹤0.01%	319
2022 Q1	$5K	Hold	81	–	–	﹤0.01%	315
2021 Q4	$6K	Buy	+81	New	+$7.08K	﹤0.01%	310

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacific Center for Financial Services's CRSP Position: Q4 2024 in Review

Pacific Center for Financial Services sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 81 shares — an estimated $3.81K sold.

Pacific Center for Financial Services first reported a position in CRSP in Q4 2021 and held it in 11 quarters. The position peaked at $6K in Q4 2021. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

Pacific Center for Financial Services reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
Pacific Center for Financial Services sold 81 CRISPR Therapeutics shares in Q4 2024, an estimated $3.81K.
Pacific Center for Financial Services first reported a position in CRISPR Therapeutics in Q4 2021 and held it in 11 quarters.
Pacific Center for Financial Services's CRISPR Therapeutics position peaked at $6K in Q4 2021.
404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on Pacific Center for Financial Services's 13F filing for Q4 2024, filed 18 Feb 2025.